Compare · MDLN vs PODD
MDLN vs PODD
Side-by-side comparison of Medline Inc. (MDLN) and Insulet Corporation (PODD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and PODD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.94B, about 4.9x PODD ($9.58B).
- Over the past year, MDLN is down 10.1% and PODD is down 55.7% - MDLN leads by 45.6 points.
- PODD has been more active in the news (7 items in the past 4 weeks vs 5 for MDLN).
- Both have 25 recent analyst ratings on file.
- Company
- Medline Inc.
- Insulet Corporation
- Price
- $36.65+2.00%
- $138.53+3.43%
- Market cap
- $46.94B
- $9.58B
- 1M return
- +11.06%
- -1.44%
- 1Y return
- -10.07%
- -55.66%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2007
- News (4w)
- 5
- 7
- Recent ratings
- 25
- 25
Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.
Latest MDLN
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
Latest PODD
- Insulet Announces Omnipod Discover Now Available in U.S.
- Barclays initiated coverage on Insulet with a new price target
- SEC Form 4 filed by Insulet Corporation
- Director Mazelsky Jonathan Jay was granted 141 shares, increasing direct ownership by 10% to 1,496 units (SEC Form 4)
- Director Huffines Robert Luther was granted 178 shares, increasing direct ownership by 7% to 2,627 units (SEC Form 4)
- Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
- Insulet Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
- Insulet Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Insulet Corporation filed SEC Form 8-K: Leadership Update